Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aytu Biopharma Inc
(NQ:
AYTU
)
2.985
-0.025 (-0.83%)
Streaming Delayed Price
Updated: 1:20 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aytu Biopharma Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Aytu BioPharma to Participate in September 2022 Investor Conferences
August 24, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
August 16, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
August 15, 2022
Via
ACCESSWIRE
Stocks That Hit 52-Week Lows On Wednesday
August 10, 2022
During Wednesday, 52 stocks hit new 52-week lows.
Via
Benzinga
Aytu BioPharma Plans To Divest / Discontinue Non Core Assets
May 17, 2022
Via
Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
August 10, 2022
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Via
Benzinga
Dow Drops Over 100 Points; Verona Pharma Shares Jump
August 09, 2022
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 09, 2022
Via
Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
August 09, 2022
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....
Via
Benzinga
Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher
August 09, 2022
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
August 09, 2022
On Tuesday, 73 companies hit new 52-week lows.
Via
Benzinga
Aytu BioPharma Announces Pricing of Public Offering
August 09, 2022
Via
ACCESSWIRE
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 09, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
August 09, 2022
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on today!
Via
InvestorPlace
Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket
August 09, 2022
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 69.6% to $1.04 in pre-market trading after Fnu Oudom reported a stake of 44% in the company in 13D.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
August 08, 2022
Via
Benzinga
Aytu BioPharma Announces Launch of Public Offering
August 08, 2022
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
August 01, 2022
Gainers Conformis (NASDAQ:CFMS) shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million.
Via
Benzinga
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 26, 2022
Via
ACCESSWIRE
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 26, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced...
From
Aytu BioPharma, Inc.
Via
AccessWire
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
July 20, 2022
Via
Benzinga
Aytu BioPharma Commences Late-Stage Genetic Disorder Study
July 20, 2022
Aytu BioPharma (NASDAQ: AYTU) has initiated the global Phase 3 PREVEnt clinical trial of Enzastaurin (AR101) for the treatment of patients with COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS).
Via
Benzinga
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
July 20, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
July 20, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of...
From
Aytu BioPharma, Inc.
Via
AccessWire
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 06, 2022
Via
Benzinga
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
July 01, 2022
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase...
Via
Benzinga
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
June 29, 2022
ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
June 13, 2022
ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma: Q3 Earnings Insights
May 16, 2022
Aytu BioPharma (NASDAQ:AYTU) reported its Q3 earnings results on Monday, May 16, 2022 at 04:02 PM. Here's what investors need to know about the announcement. Earnings Aytu BioPharma beat estimated...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.